Celebrex, Bextra Ads Draw Fire From FDA; Reminder Of “Reminder” Ad Rules
Executive Summary
An FDA "untitled" letter to Pfizer on Celebrex and Bextra is the agency's second recent objection to the company's interpretation of the boundaries of "reminder" ads
You may also be interested in...
US FDA Calls Foul On CSL Behring Hemophilia Drug Promo
Idelvion promotional materials misleadingly imply that patients can engage in high-risk activity without consequences; first letter from US biologics promo branch in three years.
Pfizer Revises Zoloft Ad After FDA Cites Lack Of Suicide Information
Pfizer is revising Zoloft (sertraline) advertisements after FDA cited the company for not incorporating updated risk information in a print ad for the antidepressant
Pfizer Revises Zoloft Ad After FDA Cites Lack Of Suicide Information
Pfizer is revising Zoloft (sertraline) advertisements after FDA cited the company for not incorporating updated risk information in a print ad for the antidepressant